12/3
09:49 pm
smmt
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/19
04:28 am
smmt
Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]
Low
Report
Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]
11/18
09:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/11
04:14 am
smmt
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/7
09:00 am
smmt
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
Low
Report
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
11/4
07:00 am
smmt
Summit Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Summit Therapeutics to Present at Upcoming Investor Conferences
10/31
07:00 am
smmt
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Low
Report
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
10/22
09:28 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
10/22
08:00 am
smmt
Summit Therapeutics Raises $500 Million in Private Placement
Low
Report
Summit Therapeutics Raises $500 Million in Private Placement
10/21
08:04 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.
10/21
07:04 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $16.00 price target on by analysts at Barclays PLC. They now have an "underweight" rating on the stock.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $16.00 price target on by analysts at Barclays PLC. They now have an "underweight" rating on the stock.
10/20
09:53 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.
10/20
07:21 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/20
06:45 am
smmt
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Medium
Report
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
10/19
06:01 pm
smmt
Here are the major earnings before the open Monday [Seeking Alpha]
Low
Report
Here are the major earnings before the open Monday [Seeking Alpha]
10/19
10:36 am
smmt
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China [Yahoo! Fi
Medium
Report
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China [Yahoo! Fi
10/19
10:30 am
smmt
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Medium
Report
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
10/19
01:21 am
smmt
Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb [Yahoo! Finance]
10/18
10:00 am
smmt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10/17
07:00 am
smmt
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
Low
Report
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
10/15
07:11 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
10/15
07:00 am
smmt
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Low
Report
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
10/13
02:00 pm
smmt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10/8
05:44 pm
smmt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10/8
01:09 am
smmt
Where is Summit Therapeutics (SMMT) Headed According to Analysts? [Yahoo! Finance]
Medium
Report
Where is Summit Therapeutics (SMMT) Headed According to Analysts? [Yahoo! Finance]